Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 14/20 | 1.00 |
| ▸ | MEN1 | O00255 | 12/20 | 1.00 |
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | GAA | P10253 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 4/20 | 0.75 |
| ▸ | THRB | P10828 | 4/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | CASP6 | P55212 | 1/20 | 0.65 |
| ▸ | CRHBP | P24387 | 1/20 | 0.60 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | RRM1 | P23921 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2029030 | 1.00 | KMT2A (1.00) | KMT2AMEN1MAPTGAAALDH1A1 | |
| SCHEMBL2029031 | 1.00 | KMT2A (1.00) | KMT2AMEN1MAPTGAAALDH1A1 | |
| SCHEMBL31301126 | 1.00 | KMT2A (1.00) | KMT2AMEN1MAPTGAAALDH1A1 | |
| SCHEMBL16323254 | 0.98 | KMT2A (0.97) | KMT2AMEN1MAPTGAAALDH1A1 | |
| SCHEMBL23761140 | 0.93 | KMT2A (0.87) | KMT2AMEN1MAPTGAAALDH1A1 | |
| SCHEMBL28039588 | 0.90 | KMT2A (0.82) | KMT2AMEN1MAPTGAAALDH1A1 | |
| SCHEMBL9179463 | 0.86 | KMT2A (0.75) | KMT2AMEN1MAPTGAAALDH1A1 | |
| SCHEMBL9179465 | 0.86 | KMT2A (0.75) | KMT2AMEN1MAPTGAAALDH1A1 | |
| SCHEMBL11895330 | 0.86 | KMT2A (0.75) | KMT2AMEN1MAPTGAAALDH1A1 | |
| SCHEMBL10049041 | 0.85 | KMT2A (0.74) | KMT2AMEN1MAPTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| US-20240417806-A1 | METHODS OF IDENTIFYING AND TREATING CANCERS UTILIZING ALTERNATIVE LENGTHENING OF TELOMERE PATHWAY (ALT+ CANCERS) | NEW YORK INSTITUTE OF TECHNOLOGY | 2024-12-19 | — | — | US | claimed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| CN-122097324-A | Application of small molecular compound HAMNO in resisting African swine fever virus infection | — | 2026-05-29 | — | — | CN | disclosed |
| CN-122097324-A | Application of small molecular compound HAMNO in resisting African swine fever virus infection | — | 2026-05-29 | — | — | CN | disclosed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | disclosed |
| WO-2025088175-A1 | ALC1 INHIBITORS FOR USE IN TREATING CANCER BY POTENTIATING THE EFFECTS OF SEVERAL CLASSES OF APPROVED CANCER DRUGS | EISBACH BIO GMBH (DE) | 2025-05-01 | — | — | WO | disclosed |
| US-20240417806-A1 | METHODS OF IDENTIFYING AND TREATING CANCERS UTILIZING ALTERNATIVE LENGTHENING OF TELOMERE PATHWAY (ALT+ CANCERS) | NEW YORK INSTITUTE OF TECHNOLOGY | 2024-12-19 | — | — | US | disclosed |
| EP-4460308-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR PREVENTING, INHIBITING OR REDUCING RISK OF METASTASIS OF A CANCER | Lixte Biotechnology, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20230310418-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR PREVENTING, INHIBITING OR REDUCING RISK OF METASTASIS OF A CANCER | LIXTE BIOTECHNOLOGY, INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2023133371-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR PREVENTING, INHIBITING OR REDUCING RISK OF METASTASIS OF A CANCER | LIXTE BIOTECHNOLOGY, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310418-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR PREVENTING, INHIBITING OR REDUCING RISK OF METASTASIS OF A CANCER | BCL3, BCL2L10, BIRC3 | KMT2A 1464/4885MEN1 1670/4885MAPT 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.